Hidradenitis suppurativa sits at the center of this dementia and brain health question.
Hidradenitis Suppurativa Biologic: this caregiver-focused guide explains what hidradenitis suppurativa biologic means in plain English, the day-to-day implications for families, and when to bring it up with a clinician. If you arrived here looking for a quick orientation on hidradenitis suppurativa biologic, the table of contents below points to the section you need; the full guide picks up after it.
Table of contents
- Table of Contents
- What Are the Biologics Finally Clearing Hidradenitis Suppurativa?
- Why Does HS Take So Long to Diagnose — and What Goes Wrong in the Meantime?
- How Do These Three Biologics Compare Head to Head?
- What Should Patients Know Before Starting a Biologic for HS?
- The Hidden Burden — Mental Health, Misdiagnosis, and Disparities in HS Care
- What Is Coming Next in the HS Treatment Pipeline?
- HS Awareness and the Road Ahead
After nearly a decade with only one approved biologic for hidradenitis suppurativa, two new treatments have finally reached patients — and the most recent one, bimekizumab (Bimzelx), approved by the FDA in November 2024, is showing the strongest clinical trial results yet for this brutally painful and widely misunderstood skin disease. In the BE HEARD II trial, 52% of patients on bimekizumab achieved meaningful clinical improvement compared to 32% on placebo, and those gains held through 48 weeks of treatment. For the estimated 1% of the global population living with HS — many of whom waited seven to ten years just to get a correct diagnosis — this represents a genuine shift in what medicine can offer.
HS is not a condition most people have heard of, but those who live with it know it intimately: recurring, deeply painful boils and abscesses that form in the armpits, groin, and other skin-fold areas, often draining pus and leaving tunneling scars beneath the skin. The disease carries metabolic, musculoskeletal, and psychological consequences that extend well beyond the skin itself. This article covers what these three FDA-approved biologics actually do, how they compare, who they work best for, and what the real limitations and costs look like — because while this is genuinely good news, it is not a simple story.
Table of Contents
- What Are the Biologics Finally Clearing Hidradenitis Suppurativa?
- Why Does HS Take So Long to Diagnose — and What Goes Wrong in the Meantime?
- How Do These Three Biologics Compare Head to Head?
- What Should Patients Know Before Starting a Biologic for HS?
- The Hidden Burden — Mental Health, Misdiagnosis, and Disparities in HS Care
- What Is Coming Next in the HS Treatment Pipeline?
- HS Awareness and the Road Ahead
- Conclusion
- Frequently Asked Questions
What Are the Biologics Finally Clearing Hidradenitis Suppurativa?
Three biologics are now FDA-approved for moderate-to-severe HS, each targeting a different piece of the inflammatory cascade that drives the disease. The first was adalimumab (Humira), a TNF-alpha inhibitor made by AbbVie, approved in 2015. It was a landmark — the first biologic approved for HS at all — and achieves HiSCR50 (a 50% reduction in clinical response score) in roughly 42–59% of patients at week 12. But for many patients, that response was incomplete or faded over time, and for years there was simply nothing else approved to try. That changed in October 2023 when the FDA approved secukinumab (Cosentyx), an IL-17A inhibitor from Novartis, making it the first new biologic for HS in nearly a decade.
In clinical trials, patients experienced fewer painful boils and inflammatory nodules over 16 weeks compared to placebo, and after a full year of treatment, more than 80% of patients had no increase in draining tunnels — a meaningful marker because tunnel formation represents some of the most disfiguring and difficult-to-treat damage HS causes. Then came bimekizumab (Bimzelx) in November 2024, a first-in-class dual IL-17A and IL-17F inhibitor from UCB. By blocking both IL-17A and IL-17F simultaneously, bimekizumab targets a broader swath of the inflammatory pathway. The BE HEARD I trial showed roughly 48% of patients hitting the primary endpoint versus 29% on placebo, while BE HEARD II showed 52% versus 32%. Long-term extension data from the BE HEARD EXT trial is anticipated by the end of 2025.
Why Does HS Take So Long to Diagnose — and What Goes Wrong in the Meantime?
One of the most damaging aspects of HS is not the disease itself but the years patients spend being told they have something else entirely. The average diagnostic delay is 7 to 10 years from symptom onset, with one German multicenter study documenting an average of 10.0 years (with a standard deviation of 9.6 years, meaning some patients wait far longer). During that delay, patients typically see three or more different physicians and receive three or more incorrect diagnoses before someone finally identifies HS. The misdiagnosis patterns are consistent and revealing: 50.3% of patients are initially told they have a simple abscess, 44.8% are diagnosed with a cyst, 31.5% are told it is acne, 14.7% receive a cellulitis diagnosis, and 13.3% are told they have MRSA. Each of these misdiagnoses leads to treatment that does not address the underlying inflammatory disease — antibiotics for an “infection” that is not truly infectious, or incision and drainage for an “abscess” that will simply recur because the root cause has not been touched.
However, the consequences of delayed diagnosis extend beyond wasted time and ineffective treatment. Research published in Karger’s Dermatology journal documents that HS patients experience metabolic, musculoskeletal, and psychological disorders alongside their skin disease. A staggering 75.6% of all HS patients undergo at least one surgical intervention, and among those with the most delayed diagnoses, roughly 90% require surgery. The risk factors for delayed diagnosis — younger age at onset, female sex, non-white ethnicity, higher BMI, and more severe disease — compound existing healthcare disparities. Women, who are three times more likely than men to develop HS in North American and European populations, and patients of color face the longest waits.
How Do These Three Biologics Compare Head to Head?
Direct head-to-head trials between the three approved biologics for HS have not been published, so clinicians and patients are left comparing across separate clinical trial programs — an imperfect exercise, since trial populations, endpoints, and protocols differ. that said, the available data offers some useful orientation. Adalimumab, the oldest option, has the longest track record and the most real-world prescribing data. Its HiSCR50 response rate of 42–59% at week 12 set the benchmark. Secukinumab shifted the conversation by targeting IL-17A rather than TNF-alpha, offering a mechanistically different option for patients who did not respond to adalimumab or lost response over time.
Its standout data point — more than 80% of patients showing no increase in draining tunnels after a year — speaks to durability, though it is worth noting that “no increase” is not the same as resolution. Bimekizumab’s dual IL-17 blockade represents the newest approach, and its trial results are competitive: 48–52% primary endpoint response versus 29–32% on placebo. The practical question for many patients is whether bimekizumab’s broader mechanism translates to better real-world outcomes, and that answer will take time. Long-term extension data expected by end of 2025 will help clarify durability. One factor that cannot be ignored is cost — bimekizumab runs approximately $7,200 per syringe (1 mL), with a standard dose requiring two subcutaneous injections. Insurance coverage and patient assistance programs vary widely, and for some patients the cost barrier will determine treatment choice more than clinical data.
What Should Patients Know Before Starting a Biologic for HS?
Starting a biologic is not a casual decision, and patients benefit from understanding what these drugs can and cannot do. Biologics for HS are approved for moderate-to-severe disease, which generally means patients with recurring inflammatory nodules and abscesses in multiple body areas. For milder disease, non-biologic options still play an important role — combined oral rifampicin and clindamycin given for 12 weeks achieves roughly a 48% HiSCR50 response rate, comparable to some biologic results, and may be appropriate as a first-line approach for patients with less extensive disease. The tradeoff between biologics and antibiotic combinations involves several considerations. Antibiotics are less expensive and do not require injection, but they carry risks of antibiotic resistance with repeated courses and are not suitable for long-term continuous use. Biologics suppress specific immune pathways, which means they come with infection risk and require monitoring, but they can be continued long-term if they are working.
Neither approach cures HS — both aim to reduce flares and prevent disease progression. Patients who have already developed extensive scarring and tunneling may need surgical intervention regardless of which medical therapy they pursue. It is also worth setting expectations honestly. Even in the best-performing clinical trials, roughly half the patients on the active drug did not meet the primary response endpoint. Biologics represent a meaningful advance, but they are not a guarantee. Patients who do not respond to one biologic may respond to another, given that the three approved drugs target different inflammatory pathways, and switching between mechanisms is a reasonable clinical strategy.
The Hidden Burden — Mental Health, Misdiagnosis, and Disparities in HS Care
HS inflicts damage that goes well beyond the skin. The disease most frequently manifests between ages 18 and 29, meaning it often arrives during the years when people are building careers, forming relationships, and establishing adult identity. The locations where HS develops — armpits, groin, buttocks, under the breasts — are areas that carry social stigma, and the draining, odorous wounds can lead to profound isolation. The psychological toll is significant, and clinicians who treat HS report high rates of depression and anxiety among their patients. The diagnostic delay problem compounds this burden.
A patient who develops painful boils at age 20 and is repeatedly told they have recurrent abscesses or poor hygiene may not receive an HS diagnosis until age 30. During that decade, they may undergo multiple unnecessary surgeries, take repeated courses of antibiotics, and internalize the message that their condition is somehow their fault. Research has identified that non-white patients, women, and those with higher BMI face the longest delays — populations that already encounter barriers in healthcare access and quality. This matters in the context of biologic treatment because earlier intervention may prevent some of the irreversible tunneling and scarring that makes advanced HS so difficult to manage. The 75.6% surgical intervention rate among HS patients reflects, at least in part, what happens when the disease progresses unchecked during years of misdiagnosis. Getting the right diagnosis sooner does not just spare patients emotional distress — it may change their long-term disease trajectory.
What Is Coming Next in the HS Treatment Pipeline?
The HS treatment landscape is expanding rapidly. Multiple additional biologics are currently in Phase 3 clinical trials, with several drug launches expected within the next five years. The treatment market, which reflects both existing and anticipated therapies, is projected to reach $4.6 billion by 2035 — a figure driven by increasing disease awareness, broader diagnostic efforts, and the arrival of new treatment options.
This pipeline matters because even three approved biologics leave significant unmet need. When roughly half of patients do not achieve adequate response to any given biologic, having more options with different mechanisms of action increases the odds that each patient can find something that works. The next generation of therapies may also target novel pathways in HS inflammation, potentially reaching patients who do not respond to current TNF-alpha or IL-17 blockade.
HS Awareness and the Road Ahead
The story of HS treatment is, in many ways, a story about what happens when a disease is poorly understood for too long. For decades, HS was undertaught in medical schools, underresearched in clinical trials, and underrecognized in exam rooms. The approval of three biologics in under a decade — after years with no approved treatments at all — reflects a genuine acceleration of interest and investment.
But medication access alone will not solve the HS problem. The 7-to-10-year diagnostic delay, the racial and gender disparities in diagnosis, and the emotional devastation of years spent misdiagnosed all require systemic changes in medical education and clinical awareness. For patients currently navigating HS, the practical message is this: biologics are no longer a single option but a growing class, and dermatologists with HS experience are the right partners for developing a treatment plan.
Conclusion
The approval of bimekizumab in November 2024 gave HS patients a third FDA-approved biologic and the first dual IL-17 inhibitor for this disease, joining adalimumab (2015) and secukinumab (2023). Clinical trial data shows meaningful improvement for many patients, with response rates ranging from 42% to 59% depending on the drug and trial. These are not cure rates, but for a disease that was essentially orphaned by the pharmaceutical industry until recently, they represent substantial progress.
The treatment pipeline suggests more options are on the way, with the market projected to reach $4.6 billion by 2035. For patients and caregivers, the most important takeaway may be the simplest: HS is a real, diagnosable, treatable inflammatory disease — not a hygiene problem, not recurrent abscesses, and not something to endure in silence. If you or someone you care for has been dealing with recurring painful boils in skin-fold areas, particularly if they have been misdiagnosed multiple times, ask for a referral to a dermatologist who treats HS. Earlier diagnosis and earlier treatment can change the course of this disease.
Frequently Asked Questions
What is hidradenitis suppurativa?
HS is a chronic inflammatory skin disease that causes painful, recurring boils and abscesses primarily in areas where skin rubs together — armpits, groin, buttocks, and under the breasts. It affects approximately 1% of the global population and is three times more common in women than men. It is not caused by poor hygiene or infection.
How many biologics are FDA-approved for HS?
Three biologics are currently FDA-approved for moderate-to-severe HS: adalimumab (Humira, approved 2015), secukinumab (Cosentyx, approved October 2023), and bimekizumab (Bimzelx, approved November 2024). Each targets a different inflammatory pathway.
Why does HS take so long to diagnose?
The average diagnostic delay is 7 to 10 years. Patients are commonly misdiagnosed with abscesses (50.3%), cysts (44.8%), acne (31.5%), cellulitis (14.7%), or MRSA (13.3%). During this delay, patients typically see three or more physicians before receiving the correct diagnosis.
Do biologics cure HS?
No. Biologics manage HS by reducing inflammation, flare frequency, and disease progression, but they do not cure the underlying condition. In clinical trials, roughly 42–59% of patients on adalimumab and 48–52% on bimekizumab achieved meaningful clinical improvement. Ongoing treatment is typically necessary.
How much do HS biologics cost?
Costs vary by drug and insurance coverage. Bimekizumab, the newest option, costs approximately $7,200 per syringe, with a standard dose requiring two injections. Patient assistance programs and insurance negotiations can significantly affect out-of-pocket costs.
Are there non-biologic treatments for HS?
Yes. For milder disease, a 12-week course of combined oral rifampicin and clindamycin achieves roughly a 48% clinical response rate. Surgical intervention is also common — 75.6% of HS patients undergo at least one surgery, particularly those with delayed diagnoses and advanced disease.
You Might Also Like
- Dry Eye Disease Drops vs. Restasis vs. Xiidra: A Comparison
- New Drug Approved for Alcohol Use Disorder — First in 20 Years
- This Glaucoma Drug Has Been Used for 50 Years — Here’s Why
Sources used for this Hidradenitis Suppurativa Biologic guide
- National Institute on Aging — Alzheimer’s and related dementias
- Alzheimer’s Association
- Mayo Clinic — Dementia
This article is informational and not medical advice. See our Editorial Policy for how we research and review content. Last reviewed June 6, 2026.
For more, see CDC — Alzheimer’s and Dementia.
